Analysts await Antares Pharma, Inc. (NASDAQ:ATRS) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.04 EPS, up 25% or $0.01 from last year’s $-0.05 per share.

At the moment 4 analysts are watching Antares Pharma, Inc. (NASDAQ:ATRS), 3 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 3 analysts have a mean sales target of 11.90 million. For the quarter ending Sep-16, 3 analysts have a mean sales target of 11.43 million whilst for the year ending Dec-16, 3 analysts have a mean target of 46.97 million.

In terms of earnings per share, 3 analysts have a -0.03 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 3 analysts have a -0.03 EPS mean target and for the quarter ending Sep-16 there are 3 estimates of -0.12 EPS.

The biggest institutional shareholders in Antares Pharma, Inc. include Armistice Capital, LLC which owns 13 million shares in the company valued at $16.02 million. Broadfin Capital, LLC is the second biggest holder with 11 million shares currently valued at 13.89 million whilst Vanguard Group Inc has 5 million shares valued at 6.35 million.

Total shares held by institutions as of the most recent company filings are 60,510,747 with a reported 12,285,989 bought and 12,438,113 sold. These holdings make up 39.08% of the company’s outstanding shares.

Currently insiders hold 12,716,044 shares in the business which makes up 8.21% of shares. The biggest holder currently is Dr. Jacques Gonella who owns 9,126,413 shares (5.89% of those outstanding), whilst Dr. Paul K. Wotton,PhD holds 937,725 (0.61% of shares outstanding) and Robert F. Apple holds 517,164 (0.33% of shares outstanding).

The stock increased 2.9891% or $0.0275 during the last trading session, hitting $8.0000. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 81.5% over the past 6 months and is uptrending.